Kerry Group Upgraded to 'Buy' by Citi on Undervalued Fundamentals

Citi has upgraded Kerry Group (KYGa.I) to a "Buy" rating, setting a new price target of €102 for the global ingredients company. The bank's analysts argue that the firm is fundamentally undervalued based on its strong financial metrics and the potential for a broader recovery in the European ingredients sector.

The Analyst's Thesis

According to a research note, Citi believes Kerry's current valuation is "difficult to justify" when compared to its fundamentals. The upgrade is based on the company's combination of capital efficiency, strong cash conversion, and an improving earnings trajectory.

The brokerage suggests that as growth returns to the sector following a volatile post-pandemic period, companies with solid returns will see their valuations improve. This returns-based approach, Citi argues, provides a more accurate measure of quality than focusing solely on near-term earnings growth.

Sector-Wide Outlook

Citi's analysis extends to the broader European ingredients sector, where it notes that investor confidence has weakened due to inconsistent performance since the COVID-19 pandemic. However, the bank maintains that the "underlying franchise quality remains strong" across the industry.

Ad

An improvement in returns and capital efficiency could support a renewed recovery in sector valuations, restoring what the bank calls the "longer-term compounder characteristics" of these businesses. This view underpins a more optimistic outlook for select companies in the space.

Peer Comparison

In its sector review, Citi provided commentary on several other major ingredients companies:

• Novonesis (NSISb.CO): Noted as the leading reinvestment-driven compounder in the group.
• Symrise (SY1G.DE): Highlighted for broad-based improvement in returns that may not be fully reflected in its current valuation.
• DSM-Firmenich (DSFIR.AS): Described as having significant recovery potential, though execution remains a key factor.
• Givaudan (GIVN.S): Its strong returns and cash conversion are considered to be already well-reflected in its valuation.
• Croda (CRDA.L): Still needs to demonstrate further progress in its operational turnaround, according to the note.